Acute exacerbation of COPD

From IDWiki

Background

  • Worsening respiratory symptoms, including dyspnea, cough, sputum production, or change in sputum

Classification

  • Mild: treated with short-acting bronchodilators only
  • Moderate: also requiring antibiotics or oral corticosteroids
  • Severe: requires emergency room visit or hospital admission
    • No respiratory failure: RR 20-30, no use of accessory muscles, no mental status changes, hypoxemia improves with ≤35% FiO2 by Venturi mask, and no increase in PaCO2
    • Non-life-threatening acute respiratory failure: RR >30, using accessory muscles, no mental status changes, hypoxemia improves with ≤30% FiO2 by Venturi mask, hypercarbia with PaCO2 50-60 mmHg
    • Life-threatening acute respiratory failure: RR>30, using accessory muscles, mental status changes, hypoxemia requiring FiO2 >40%, hypercarbia >60 mmHg or pH ≤7.25

Etiology

  • Infections (bacterial or viral)
  • Air pollution and ambient temperature
  • Pulmonary embolism
  • Congestive heart failure

Clinical Manifestations

  • Dyspnea, cough
  • Increase sputum production, sometimes purulent

Complications and Prognosis

  • 11% in-hospital mortality
  • 23-33% 6-month or 1-year mortality
  • 50% 2-year mortality
  • Symptoms usually last 7 to 10 days, but up to 20% are still not back to baseline by 8 weeks

Differential Diagnosis

Investigations

  • CXR to rule out pneumonia, pneumothorax, pleural effusion
  • ECG and troponins to rule out ACS
  • D-dimer or US Doppers to rule out PE
  • CBC
  • ABG in severe exacerbation
  • Sputum cultures to help guide later therapy
  • Spirometry at some point during their hospitalization, if it's the first presentation

Management

Severe Exacerbations

  • Assess patient, get ABG and chest x-ray
  • Start supplemental oxygen, get serial ABG/VBGs/SpO2Puffers
    • Increase dose and frequency of short-acting bronchodilators
    • Use both short-acting β-2-agonists (salbutamol) and anticholinergics (ipratropium)
    • Add long-acting bronchodilators (e.g. tiotropium) when patient is more stable
    • Consider spacers or nebulizers when needed (though no difference between the two)
  • Steroids: prednisone 40mg for 5 days, or equivalent
  • Antibiotics: if purulent/sputum change
  • Non-invasive ventilation
    • Decreases mortality and prevents intubation
    • Indicated if any of the following:
      • Respiratory acidosis (pH ≤7.35 and pCO2 ≥45 mmHg)
      • Severe dyspnea with increased work of breathing or concern for fatigue
      • Resistant hypoxia despite supplemental oxygen
  • Invasive ventilation is indicated if:
    • Failure of or inability to tolerate non-invasive ventilation
    • Respiratory or cardiac arrest
    • Decreased level of consciousness or psychomotor agitation not controlled by sedation
    • Massive aspiration or persistent vomiting
    • Inability to control respiratory secretions
    • Severe hemodynamic instability despite appropriate management
    • Severe arrhythmias
    • Life-threatening hypoxemia
  • Routine:
    • Monitor fluid balance
    • DVT prophylaxis
    • Treat comorbidities including heart failure, arrhythmias, and pulmonary embolism
    • Vitamin D replacement if deficient

Further Reading